TFX

Teleflex’s first quarter was marked by substantial year-on-year revenue growth, which outpaced Wall Street’s expectations and triggered a significant positive market reaction. Management credited the expansion to the inclusion of the recently acquired Vascular Intervention business and ongoing momentum across core product lines, particularly in vascular and surgical categories. Interim CEO Stuart Randle pointed to “strong execution” and noted that surgical instrument sales benefited from some favorable timing of orders, while integration activities in interventional products caused some temporary disruption. The quarter also included quality remediation costs related to supplier recalls, which contributed to the notable pressure on operating margins. Is now the time to buy TFX? Find out in our full research report (it’s free). Revenue: $548.3 million vs analyst estimates of $533.4 million (32.3% year-on-year growth, 2.8% beat) Adjusted EPS: $1.39 vs analyst estimates of $1.22 (13.9% beat) Adjusted EBITDA: $119.9 million vs analyst estimates of $107.4 million (21.9% margin, 11.7% beat) Management reiterated its full-year Adjusted EPS guidance of $6.40 at the midpoint Operating Margin: 3.7%, down from 18.3% in the same quarter last year Constant Currency Revenue rose 5.1% year on year (-3.8% in the same quarter last year) Market Capitalization: $5.76 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Michael Matson (Needham & Company) asked about the potential for slower Q2 growth due to recalls and integration challenges. CFO John Deren acknowledged Q2 could be affected but expects acceleration in the second half as integration disruptions subside. Jayson Bedford (Raymond James) inquired about the balanced growth across segments and what will drive future outperformance. Deren highlighted strong performance in vascular and surgical, with interventional expected to become the main growth engine over time due to increased R&D focus. Matthew Taylor (Jefferies) questioned how input cost inflation, especially logistics, may affect margins. Deren noted logistics and distribution costs rose late in the quarter but beli...

The market was pleased with the recent earnings report from Teleflex Incorporated (NYSE:TFX), despite the profit numbers being soft. Our analysis suggests that investors may have noticed some promising signs beyond the statutory profit figures. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. To properly understand Teleflex's profit results, we need to consider the US$197m expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. In the twelve months to March 2026, Teleflex had a big unusual items expense. All else being equal, this would likely have the effect of making the statutory profit look worse than its underlying earnings power. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Having already discussed the impact of the unusual items, we should also note that Teleflex received a tax benefit of US$39m. This is meaningful because companies usually pay tax rather than receive tax benefits. We're sure the company was pleased with its tax benefit. However, the devil in the detail is that these kind of benefits only impact in the year they are booked, and are often one-off in nature. In the likely event the tax benefit is not repeated, we'd expect to see its statutory profit levels drop, at least in the absence of strong growth. While we think it's good that the company has booked a tax benefit, it does mean that there's every chance the statutory profit will come in a lot higher than it would be if the income was adjusted for one-off factors. In the last year Teleflex received a tax benefit, which boosted its profit in a way that might not be much more sustainable than turning prime farmland into gas fields. But on the other hand, it also saw an unusual item depress its profit. Based on these factors, we think that Teleflex's profi...

WAYNE, Pa., May 15, 2026--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 30, 2026, to shareholders of record at the close of business on May 25, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260515138502/en/ Contacts TeleflexLawrence KeuschVice President, Investor Relations and Strategy [email protected] 610-948-2836

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Teleflex (TFX) is back in focus after first quarter 2026 results surpassed analyst expectations on both revenue and earnings, while management reaffirmed its full year guidance and outlined sizeable divestitures, buybacks, and planned debt reduction. See our latest analysis for Teleflex. The share price has picked up recently, with a 7 day share price return of 6.91% and a 90 day share price return of 20.65%, but the 3 year total shareholder return is down 46.45%. Current momentum therefore follows a much weaker long term record as investors weigh Q1 results, portfolio moves, the new CEO announcement, and an ongoing product recall. If Teleflex’s recent moves have you rethinking your healthcare exposure, it could be a good moment to see what else is on the radar with 33 healthcare AI stocks. With the stock up strongly in recent months but still carrying a weak multi year record and trading below the average analyst price target, is this an undervalued restructuring story, or has the market already priced in the next leg of growth? Teleflex's most followed narrative pegs fair value at $129.25, almost exactly in line with the last close of $129.03, yet still flags the stock as about 20% undervalued based on its own framework and assumptions. Read the complete narrative. Behind that fair value is a detailed earnings roadmap, with revenue, margins, and future P/E all working together. Curious which of those levers does the heavy lifting in this narrative, and how much change it assumes from today. Result: Fair Value of $129.25 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on Teleflex managing pressure in weaker lines like UroLift and executing cleanly on the BIOTRONIK integration, where setbacks could quickly challenge this thesis. Find out about the key risks to this Teleflex narrative. If this mix of optimism and concern feels familiar, now is a good time to look at the data yourself and decide where you stand, starting with 2 key rewards and 3 important warning signs. Before moving on, consider building a broader watchlist so you are not relying on a single stock story when new information hits the market. Target sturdier balance sheets and steady fundam...

Teleflex Inc. TFX posted first-quarter 2026 adjusted earnings per share (EPS) from continuing operations of $1.39, down 3.5% from the year-ago quarter’s figure. However, the metric topped the Zacks Consensus Estimate by 14.75%. GAAP loss per share was 11 cents compared to EPS of $1.14 in the prior-year period. First-quarter revenues from continuing operations were $548.26 million, up 32.3% year over year and surpassed the Zacks Consensus Estimate by 2.72%. On a pro forma adjusted constant currency basis — which includes prior-year revenues from the acquired Vascular Intervention business, and excludes foreign exchange and revenues from products discontinued after the 2025 strategic realignment — revenues rose 5.1% in the quarter. Since the announcement on May 7, shares of the company have fallen 2% to close the session at $131.56 yesterday. The Vascular segment recorded pro forma adjusted revenues of $236.8 million, up 8.1% on a reported basis and 4.8% on a pro forma adjusted constant currency basis. Growth was mainly driven by hemostatic products in the central venous and other access portfolio. Teleflex Incorporated price-consensus-eps-surprise-chart | Teleflex Incorporated Quote The Interventional business registered pro forma adjusted revenues of $204.7 million, up 104.4% on a reported basis and 3% on a pro forma adjusted constant currency basis. Performance was led by the intraosseous, right heart catheters and complex catheters. The Surgical segment recorded pro forma adjusted revenues of $106.8 million, up 12.4% on a reported basis and up 9.9% on a pro forma adjusted constant currency basis. Growth was led by the strong performance in the ligation clip and some timing of orders in the instrument portfolio. The gross profit was $307.4 million, up 20.4% year over year. The gross margin contracted 559 basis points (bps) to 56.1% due to a 51.6% rise in the cost of goods sold. Overall, the adjusted operating profit was $37 million, down 52.1% year over year. The adjusted operating margin contracted 1189 bps to 6.8%. Teleflex exited the first quarter of 2026 with cash and cash equivalents of $309.4 million compared with $378.6 million at the end of 2025. Net cash flow provided by operating activities from continuing operations was $46.7 million compared with $27.7 million in the year-ago period. On a GAAP basis, the company continues to expect full-year 202...

Management is executing a major portfolio pivot, divesting acute care, interventional urology, and OEM businesses to focus on high-acuity hospital markets and core critical care. The acquisition of BIOTRONIK's Vascular Intervention business is being integrated to expand the coronary and peripheral intervention footprint, despite temporary disruption from sales force realignment. First quarter revenue growth of 5.1% was driven by strong performance in hemostatic products and ligation clips, alongside lumpy but positive timing in surgical instrument orders. Operating margins were impacted by transient factors including $90 million in stranded costs, higher logistics expenses due to geopolitical conflicts, and quality remediation charges from third-party supplier recalls. The company is shifting toward a higher-growth profile, targeting a 23% steady-state adjusted operating margin once divestitures close and transition service agreements (TSAs) take effect. A multiyear restructuring plan is underway to achieve $50 million in annual pretax savings by mid-2028, with savings expected to accelerate in the second half of 2026. Management reaffirmed full-year pro forma revenue growth guidance of 4.5% to 5.5%, anticipating accelerated momentum in the second half of the year as integration disruptions subside. The company accelerated its capital return timeline, initiating opportunistic share repurchases in Q2 2026 ahead of the previously planned post-divestiture schedule. Strategic divestitures remain on track for the second half of 2026, with the OEM sale expected to close in Q3 following the expiration of the HSR waiting period. Guidance for 2026 assumes $105 million in net interest expense and does not yet factor in the benefits of the planned $800 million debt reduction or $1 billion share buyback. Clinical milestones for the Freesolve magnesium scaffold include a late 2027 European data readout and the initiation of a U.S. pivotal trial in 2026. Two third-party supplier recalls for vascular and interventional kit components necessitated a cost provision in Q1 and may cause elevated back orders through Q2. The FTC issued a second request for information regarding the sale of the acute care and interventional urology businesses, though management still expects a 2026 close. Tariffs represent a $33 million headwind in the 2026 guidance, with any potential refunds fo...

Image source: The Motley Fool. Thursday, May 7, 2026 at 8 a.m. ET Interim President and Chief Executive Officer — Stuart Randle Chief Financial Officer — John Deren Chairman of the Board — Lawrence Keusch Stuart Randle: Thank you, Larry, and good morning, everyone. Before I review the first quarter 2026 results, I will provide an update on our strategic objectives and our commitment to maximize long-term shareholder value. Teleflex has made demonstrable progress optimizing its portfolio and positioning the company for the meaningful opportunities ahead of us. In July 2025, we completed the acquisition of BIOTRONIK's Vascular Intervention business, expanding our coronary intervention portfolio and establishing a global footprint in the fast-growing peripheral intervention market. In December 2025, we announced agreements to sell the acute care, interventional urology and OEM businesses as part of our overall transformation plan, creating a more focused medical technologies leader with a higher forward revenue CAGR, greater exposure to core critical care and high-acuity hospital markets and a more focused portfolio across Vascular Access, Interventional and Surgical. These strategic divestitures remain on track to close in the second half of 2026. On OEM, we reached an important milestone in March when the Hart-Scott-Rodino waiting period expired. We are focused on completing the remaining closing conditions with a target of closing in the third quarter of 2026. Separately, in March, Teleflex and the buyer of the acute care and interventional urology businesses each received a second request for additional information from the U.S. Federal Trade Commission. We are cooperating with the FTC and continue to expect that transaction to close in the second half of 2026. We remain committed to using the proceeds from the divestitures to fund a share repurchase program of up to $1 billion and to reduce debt by $800 million, reflecting our disciplined approach to capital allocation and our focus on enhancing shareholder value and financial flexibility. We now expect to begin opportunistic share repurchases in the open market during the second quarter of this year, ahead of the previously anticipated timing of following the completion of the strategic divestitures. This action reflects our confidence in the value of the business, the progress we are making on our transf...

For the quarter ended March 2026, Teleflex (TFX) reported revenue of $548.26 million, down 21.8% over the same period last year. EPS came in at $1.39, compared to $2.91 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $533.74 million, representing a surprise of +2.72%. The company delivered an EPS surprise of +14.75%, with the consensus EPS estimate being $1.21. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Teleflex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Surgical: $106.8 million compared to the $102.19 million average estimate based on 11 analysts. The reported number represents a change of +1% year over year. Revenues- Interventional: $204.7 million compared to the $210.39 million average estimate based on eight analysts. Revenues- Vascular: $236.8 million compared to the $223.03 million average estimate based on eight analysts. View all Key Company Metrics for Teleflex here>>> Shares of Teleflex have returned +3.5% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teleflex Incorporated (TFX) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

WAYNE, Pa., May 07, 2026--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the first quarter ended March 31, 2026. First quarter 2026 continuing operations financial summary1 Revenue from continuing operations of $548.3 million, up 32.3% compared to the prior year period, and up 5.1% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $(0.11), compared to $1.14 in the prior year period Adjusted diluted EPS from continuing operations of $1.39, compared to $1.44 in the prior year period 2026 continuing operations guidance summary1 Maintaining GAAP revenue growth guidance range of 14.40% to 15.40% Maintaining pro forma adjusted constant currency revenue growth guidance range of 4.50% to 5.50%2 Maintaining GAAP EPS from continuing operations guidance range of $2.90 to $3.20 Maintaining Adjusted diluted EPS from continuing operations guidance range to $6.25 to $6.55 Includes full year impact of stranded costs estimated to be $90 million Excludes expected benefits from transition services ("TS") and manufacturing services ("MS") agreements that come into effect upon closing of Strategic Divestitures, which we anticipate will fully offset stranded costs on an annualized basis Excludes impact of repurchases under previously announced $1 billion share repurchase program and expected debt paydown of ~$800 million primarily funded by closing of Strategic Divestitures "Our first-quarter performance reflects disciplined execution and meaningful progress against our transformation plan," said Stuart Randle, Teleflex's Interim President and Chief Executive Officer. "We delivered a strong start to the year, with 5.1% pro forma adjusted constant currency revenue growth year-over-year, and we continue to expect our two strategic divestitures to close in the second half of 2026. We remain committed to using the majority of the net proceeds from the sales transactions to return capital to shareholders through our $1 billion share repurchase authorization, while also reducing debt by $800 million to enhance financial flexibility and support future growth. These actions are advancing our strategy to optimize our portfolio, strengthen Teleflex's position as a focused medical technologies leader and drive long-term value creation." Mr. Randle continued, "We recently announced the a...

WAYNE, Pa. (AP) — WAYNE, Pa. (AP) — Teleflex Inc. (TFX) on Thursday reported a loss of $8.2 million in its first quarter. On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 18 cents. Earnings, adjusted for amortization costs and restructuring costs, came to $1.39 per share. The results surpassed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $1.21 per share. The medical equipment maker posted revenue of $548.3 million in the period, also surpassing Street forecasts. Nine analysts surveyed by Zacks expected $533.7 million. Teleflex expects full-year revenue in the range of $2.28 billion to $2.3 billion. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TFX at https://www.zacks.com/ap/TFX

Teleflex (TFX) reported Fiscal Q1 adjusted earnings from continuing operations Thursday of $1.39 per

Teleflex (TFX) came out with quarterly earnings of $1.39 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $2.91 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +14.75%. A quarter ago, it was expected that this medical equipment maker would post earnings of $3.73 per share when it actually produced earnings of $1.93, delivering a surprise of -48.26%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Teleflex, which belongs to the Zacks Medical - Instruments industry, posted revenues of $548.26 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 2.72%. This compares to year-ago revenues of $700.67 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Teleflex shares have added about 1% since the beginning of the year versus the S&P 500's gain of 7.6%. While Teleflex has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Teleflex was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Bu...